Skip to main content

An update on lungs and federal budget issues

This is also from the American Thoracic Society's Washington letter today. It's an update on how the funding for various government programs impacting lung diseases and lung disease research is doing in the Senate. I couldn't copy the chart mentioned, but if you'd really like to see it I'll send it to you, along with where to subscribe to the newsletter if you'd like to do it yourself.


Senate Panel Approves 2011 Health Research and Services Funding


The FY2011 appropriations bills have been moving through House and Senate subcommittees and full appropriations committee's over the past few weeks. On July 29, the Senate Appropriations committee, chaired by Sen. Inouye (D-HI), approved the FY2011 Labor-HHS-ED Appropriations bill, following subcommittee action earlier in the week. The Senate bill proposes $577.8 billion for the Department of Health and Human Services, a decrease of $32.456 billion over FY2010.

The Senate Labor-HHS bill includes a $1 billion funding increase (+3.2%) for the NIH in 2011. However, this increase is based on NIH's appropriation for 2010, and does not factor in the 2010 NIH American Recovery and Reinvestment Act (ARRA) funding of $6.5 billion. The House Labor-HHS subcommittee, which met earlier this month, provided the same $1 billion increase for NIH in its FY2011 Labor-HHS bill.

The Senate bill provides $6.905 billion for the CDC, a 1.8% increase over the FY2010 funding level and $123 million over the House bill's proposed funding for CDC. Within CDC's budget, the Senate bill did not adopt the $1.2 million cut to the domestic tuberculosis control program proposed by the President's budget as the House did, and instead kept the program at the FY2010 funding level of $144.2 million.

Other highlights from Senate Labor-HHS bill include:
• $50 million for new Cures Acceleration Network within the Office of the NIH director;
• An increase of almost 80% for the CDC's Office of Smoking and Health. This funding is targeted to the CDC's efforts to analyze tobacco products and smoke following passage of the FDA regulation of tobacco bill and funding for media campaign to prevent youth smoking;
• A 21% increase for the National Institute of Occupational Health Research (NIOSH), much of it targeted for World Trade Center-related illness research;
• $251 million for a new state block grant on chronic disease prevention at CDC; and
• $40 million for CMS to support the creation of community-based patient-centered medical homes.

The Senate also approved the FY2011 Military Construction and VA Appropriations bill, which includes a 1.5% funding increase for the VA Research program, proposing a total of $590 million for the program in FY2011, and the Foreign-Operations bill, which includes flat funding at the FY2010 level of $225 million for USAID's tuberculosis program. The Senate has not yet acted on the 2011 Interior-Environment Appropriations bill, which includes the EPA budget. The House subcommittee has proposed a 2.6% cut to the EPA budget following the almost 40% funding increase for the agency in 2010.

The next step for the FY2011 Labor-HHS Appropriations bill is a vote by the full House Appropriations Committee. As the Congress is scheduled to adjourn within the next few days, this action appears unlikely to occur until September when Congress returns from its break. It is expected that due to the upcoming election, ultimately the final FY2011 appropriations bills will be delayed until after the election.

Proposed funding levels for specific programs and agencies that the ATS monitors at the NIH, CDC, VA and USAID are listed in several charts below. The House subcommittee has not released all of the program funding levels. We will share the proposed House and Senate funding for all programs once we have it.

Comments

Popular posts from this blog

Ratner's Cheesecake

Here's another recipe from Toby! Thanks Toby......and I'll get the others posted soon! Ratner's Cheesecake and plain cookies Ratner's was a Jewish dairy restaurant in the lower East Side of Manhattan. This recipe, from my disintegrating, no longer in print Ratner's cookbook, is the closest I've ever gotten to reproducing the rich, heavy cheesecake my mother made when I was a kid. It's worth the time it takes to prepare and every last calorie. Dough Can be prepared in advance. Makes enough for two cakes. Can be frozen or used to make cookies – see recipe below. 1 cup sugar 1 teaspoon vanilla extract 1 cup shortening 1 teaspoon lemon extract 1 cup butter 2 eggs 3 cups sifted cake flour ½ teaspoon salt 2 cups all purpose flour 1 teaspoon baking powder 1. In a bowl, combine all ingredients with hands. Refrigerate 3 -4 hours, or preferably overnight. Filling (for

The next generation with Hermansky-Pudlak Syndrome

I'm so behind on posting about the trip to Puerto Rico. Since the episode of Mystery Diagnosis on Hermansky-Pudlak Syndrome ran right after we got home, it's been a little busy. These, however, are my favorite pictures from Puerto Rico. I know, not pretty senery etc - but these little guys and gals inspire me. They are the next generation of folks with HPS, and if we keep up the hard work, they will live better lives because of it. They motivate me.

Some good news about Pirfenidone

Below is a press release from Intermune, the company that makes Pirfenidone. They have essentially reviewed the various clinical trials going on, and decided that Pirfenidone is safe and well tolerated. That would pretty much go along with what we've observed in the HPS community as well. We have a few folks that have been on the drug since the late 90s and continue to do well. Of course, as a journalist, I do have to say consider the source - but at the same time, as someone in a Pirfenidone trial, it's good to know. Results of Comprehensive Safety Analysis of pirfenidone In IPF Patients Presented At European Respiratory Meeting - Analysis shows safety and tolerability of pirfenidone across four clinical trials - VIENNA, Sept. 14 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: ITMN ) today announced that the results of a comprehensive review of safety data from four clinical studies were presented at the 2009 European Respiratory Society Annual Congress in Vienna, Austria